Cooper Companies director Lawrence Kurzius buys $539,150 of stock after earnings miss
The insider purchase arrives as analysts cut targets and one downgrades the contact-lens and surgical devices maker.

Lawrence Erik Kurzius, a director of The Cooper Companies (NASDAQ:COO), bought 10,000 shares of the company's common stock on September 14, 2026, at $53.915 apiece, for a total of $539,150. The purchase lifts his direct holding to 21,099 shares.
The source report notes the shares were bought below the stock's current price of $62.65, a gap of roughly 16 percent. Such a spread can look like well-timed buying, though a single filing does not reveal a director's motive, and insider purchases are only one signal among many.
The buy follows a difficult third quarter of fiscal 2026. Revenue fell short of expectations, while earnings per share matched consensus after tariff adjustments, according to Needham, which cut its price target to $73 but kept a Buy rating.
Other brokers were more cautious. Mizuho lowered its target from $85 to $75, pointing to weak sales growth at CooperVision and a muted outlook for the first half of fiscal 2027. William Blair downgraded the shares to Market Perform from Outperform, citing inventory destocking and the company's decision not to sell its CooperSurgical division.
Piper Sandler held a Neutral rating with a $59 target and addressed questions about possible strategic changes. Stifel kept a Buy rating and a $70 target, projecting 3.1 percent growth for CooperVision in fiscal 2027, below consensus estimates.
The InvestingPro analysis cited in the report puts the stock at a price-to-earnings ratio of 21.67 and a PEG ratio of 0.49, and notes that management has also been buying back shares. Those are the data provider's assessments, not independent verification of undervaluation.
The picture is one of insiders and the company signalling confidence while the analyst community is divided over growth and strategy. Whether the director's purchase proves prescient will depend on CooperVision's recovery and on how the company resolves questions over CooperSurgical. Source: Investing.com.